Precision medicine in non-small cell lung cancer: Current applications and future directions
Advances in biomarkers, targeted therapies, and immuno-oncology have transformed the
clinical management of patients with advanced NSCLC. For oncogene-driven tumors, there …
clinical management of patients with advanced NSCLC. For oncogene-driven tumors, there …
TrkB/BDNF signaling could be a new therapeutic target for pancreatic cancer
Y Oyama, S Nagao, LIN Na, K Yanai… - Anticancer …, 2021 - ar.iiarjournals.org
Abstract Background/Aim: Tropomyosin-related kinase B (TrkB)/brain-derived neurotrophic
factor (BDNF) signaling plays a role in inducing malignant phenotypes in several aggressive …
factor (BDNF) signaling plays a role in inducing malignant phenotypes in several aggressive …
[HTML][HTML] Pre-clinical modelling of ROS1+ non-small cell lung cancer
M Terrones, KO de Beeck, G Van Camp… - Lung Cancer, 2023 - Elsevier
Non-small cell lung cancer (NSCLC) is a heterogeneous group of diseases which accounts
for 80% of newly diagnosed lung cancers. In the previous decade, a new molecular subset …
for 80% of newly diagnosed lung cancers. In the previous decade, a new molecular subset …
Investigating the mechanisms of acquired resistance to ALK inhibitors in EML4-ALK-driven lung cancer
AR Paliouras - 2019 - search.proquest.com
Targeted therapies have had a great impact on the management of oncogene-driven non-
small cell lung cancer, where a subset of lung adenocarcinomas is driven by the EML4-ALK …
small cell lung cancer, where a subset of lung adenocarcinomas is driven by the EML4-ALK …